Compare · NTRA vs NVTA
NTRA vs NVTA
Side-by-side comparison of Natera Inc. (NTRA) and Invitae Corporation (NVTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and NVTA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $31.81B, about 13.7x NVTA ($2.31B).
- NTRA has hit the wire 16 times in the past 4 weeks while NVTA has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 18 for NVTA).
- Company
- Natera Inc.
- Invitae Corporation
- Price
- $222.11+4.79%
- $0.09-77.21%
- Market cap
- $31.81B
- $2.31B
- 1M return
- +7.37%
- -
- 1Y return
- +34.11%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- 2015
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 18
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Latest NTRA
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $335,091 worth of shares (1,652 units at $202.84) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 140,643 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $291,684 worth of shares (1,438 units at $202.84) as part of a pre-agreed trading plan, decreasing direct ownership by 0.77% to 185,782 units (SEC Form 4) (withholding tax)
Latest NVTA
- Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
- Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
- Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases
- Labcorp Announces Winning Bid for Select Assets of Invitae
- Invitae Enters into Agreement with Labcorp for Sale of Business
- Invitae Publishes its Environmental, Social and Governance (ESG) Report
- Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
- Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
- Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
- Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting